Surrozen filings document a biotechnology issuer focused on Wnt signaling and antibody technologies for ophthalmic disease. Recent Form 8-K reports disclose operating results, financial condition, pipeline business updates for SZN-8141 and related retinal disease programs, and collaboration and license revenue tied to research milestones.
The company's regulatory reports also record governance and compensation matters, including board and executive changes and inducement equity arrangements, along with material-agreement disclosures such as the termination of the TCGFB collaboration for antibody discovery services. Cover-page data and exhibits identify Surrozen common stock and redeemable warrants as part of the public-company capital structure.
On October 20, 2026, three investment partnerships exercised Surrozen, Inc. (SRZN) Second Tranche Units purchased in a private placement and acquired, respectively, 485,830, 548,653, and 517,241 common shares: The Column Group III, LP; The Column Group III-A, LP; and The Column Group Opportunity III, LP. Each unit included one common share and one-half of a Series E Common Warrant. The unit price was $11.60, comprising $11.5375 per share and $0.0625 attributable to accompanying warrants; the warrants have an $11.54 exercise price. No Rule 10b5-1 plan is reported.
The securities are held by the partnerships. Managing partners Peter Svennilson, identified as a ten percent owner, and Tim Kutzkey, a member of Surrozen's board, may be deemed to share voting and investment power; they disclaim beneficial ownership except to the extent of their respective pecuniary interests.
Surrozen, Inc. (SRZN)'s October 20, 2026 private placement included unit purchases by three venture-capital partnerships. The Column Group III, LP purchased 485,830 common shares and 242,915 Series E Common Warrants for $11.60 per unit, or $5,635,628.00 in aggregate. The Column Group III-A, LP purchased 548,653 shares and 274,327 warrants for $11.60 per unit, or $6,364,374.80 in aggregate. The Column Group Opportunity III, LP purchased 517,241 shares and 258,620 warrants for $11.60 per unit, or $5,999,995.60 in aggregate.
Tim Kutzkey, a member of Surrozen's board of directors, and Peter Svennilson, a managing partner of The Column Group III GP, LP and managing member of TCG Opportunity III GP, LLC, are each listed as beneficially owning 3,824,612 shares, or 21.5%, with shared voting and dispositive power through affiliated entities. The statement says they may be deemed to share that power and disclaim beneficial ownership except to the extent of their pecuniary interests.
Surrozen, Inc. director and 10% owner Tim Kutzkey reported October 20, 2026 transactions through The Column Group III, LP, The Column Group III-A, LP, and The Column Group Opportunity III, LP. The reported activity included disposition of rights to buy 728,745, 822,980, and 775,861 Second Tranche Units, alongside acquisition of the units’ common shares and Series E warrants in Surrozen’s private placement at $11.60 per unit. Each unit consists of one common share and one-half of a Series E Common Warrant. The transactions were not reported as made under a Rule 10b5-1 plan.
Surrozen, Inc. (SRZN) completed the second and final tranche of its March 2025 private placement on October 20, 2026, generating approximately $95.1 million in gross proceeds before placement agent fees and other expenses. The closing issued 5,741,605 common shares, pre-funded warrants exercisable for 2,456,500 shares, and Series E warrants to purchase 4,099,052 shares. The common-share purchase price was $11.60, and Series E warrants carry an $11.54 exercise price.
Following closing, Surrozen reported approximately 17.8 million common shares outstanding, 3.8 million shares issuable upon exercise of pre-funded warrants, and 9.1 million shares issuable upon exercise of outstanding common stock warrants. It expects cash, cash equivalents and marketable securities to provide runway into 2029, including funding for completion of the SZN-8141 DUET Phase 1b/2a study and initial Phase 1b development of SZN-8143. First patient dosing in DUET is expected in the fourth quarter of 2026, with initial data expected in the second half of 2027. Surrozen agreed to file a resale registration statement within 30 calendar days after closing and use reasonable best efforts to have it declared effective promptly, and no later than 90 calendar days (or 120 calendar days after a full SEC review).
Surrozen, Inc. (SRZN) is the issuer named in a Schedule 13G/A reporting that Boxer Capital Management, LLC, Boxer Holdings, LP, Boxer Holdings GP, LLC, and Aaron Davis each reported the same beneficial ownership position: 1,360,683 shares, or 11.6%, as of September 30, 2026. Each cover page lists shared voting power and shared dispositive power over 1,360,683 shares.
Surrozen, Inc. (SRZN) announced FDA clearance of the IND for SZN-8141, allowing the program to advance into clinical development. The IND became effective after the statutory 30-day review. SZN-8141 is a bifunctional Wnt agonist and vascular endothelial growth factor antagonist antibody being developed as an intravitreal injection for diabetic macular edema. Surrozen expects to dose the first patient in the DUET Phase 1b/2a study in the fourth quarter of 2026, with initial data expected in the second half of 2027.
The clearance satisfies the second closing milestone under Surrozen's March 2025 two-tranche private placement. The second closing is expected to provide approximately $95.1 million in gross proceeds, before placement agent fees and other expenses, and is expected on or about October 20, 2026, subject to applicable closing conditions. Proceeds are expected to support SZN-8141, SZN-8143 and broader operating activities. After closing, Surrozen expects to file an S-3 resale registration for common shares and shares issuable upon exercise of pre-funded and Series E common stock warrants; the registration rights agreement requires filing no later than 30 calendar days following closing.
Surrozen, Inc. (SRZN) is the issuer in a Schedule 13G listing 885,000 shares, or 7.5%, for each of four filers: Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz. The ownership statement says Commodore Capital LP may be deemed to beneficially own the shares as investment manager to Commodore Master; Atkinson and Kramarz are managing partners who exercise investment discretion. The cover pages report shared voting and dispositive power over 885,000 shares and zero sole voting or dispositive power. The 7.5% calculation uses 11,753,558 shares reported as issued and outstanding as of August 4, 2026.
Braidwell LP and affiliated reporting persons report beneficial ownership of Surrozen, Inc. common stock. As of June 30, 2026, they may be deemed to beneficially own 460,753 shares of common stock, representing approximately 3.9% of the class.
The position consists of 390,753 shares directly owned by Braidwell Partners Master Fund LP and 70,000 shares that the fund has the right to acquire within 60 days upon exercise of warrants. All 460,753 shares are reported with shared voting and dispositive power and no sole voting or dispositive power. The percentage is calculated using 11,610,371 shares outstanding as of May 4, 2026, plus the warrant shares, under Rule 13d-3(d)(1)(i) of the Exchange Act. The filing notes that the holding represents ownership of five percent or less of the class.
Boxer Capital Management, LLC and affiliated entities, together with Aaron Davis, report beneficial ownership of Surrozen, Inc. common stock on an amended Schedule 13G. As of June 30, 2026, the group beneficially owned 1,039,017 shares of common stock, representing 8.9% of the class, based on 11,610,371 shares outstanding as of May 4, 2026. The Reporting Persons have no sole voting or dispositive power and instead report shared voting and shared dispositive power over all 1,039,017 shares.
StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross report beneficial ownership of 602,798 shares of Surrozen, Inc. common stock. This includes 273,140 shares of common stock and 329,658 shares issuable upon exercise of Series A, B, and E warrants, all subject to a 9.99% Beneficial Ownership Limitation.
Based on 11,610,371 shares outstanding as of May 4, 2026 (plus the warrants counted under Rule 13d-3(d)(1)(i)), the Reporting Persons may be deemed to beneficially own 5.0% of the common stock. They report no sole voting or dispositive power, with shared voting power over 543,495 shares and shared dispositive power over all 602,798 shares.